Clinical trial NCT00790530: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Official title: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Keywords: Diabetes
Information Technology
Health Plans
Lead sponsor: Harvard Pilgrim Health Care
Sponsor class: OTHER
Collaborators: name: American Diabetes Association
First posted: 2008-11-13
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.

Detailed description: Randomly allocate a total of 1200 health plan members with diabetes to automated telephone outreach with speech recognition (ATO-SR; N = 600) or usual care (N = 600). The intervention is a series of three calls, using automated calls, originating from the health plan, using interactive speech recognition technology, spaced approximately 4-6 weeks apart, to encourage participants to fulfill the recommended testing (dilated eye examinations, glycated hemoglobin, LDL-cholesterol, microalbumin) that had not been performed received in the preceding year.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Diabetes, defined as either 1) filled a prescription for insulin or an oral hypoglycemic agent; or, 2) had two outpatient or one inpatient or two outpatients encounter claims with an ICD9-CM or CPT code indicating diabetes.
* Gap in a key diabetes management metric as evidenced by no claim for a dilated eye examination in the prior 15 months and no claim for one or more of the following tests: glycated hemoglobin, LDL-cholesterol, or microalbumin. (Individuals with evidence of having received ACE-inhibitors or angiotensin receptor blockers were considered to have had a microalbumin test.)

Exclusion Criteria:

* No primary care clinician in the data base
* Those who had previously asked the health plan to exclude them from research or quality improvement
* Women whose claim records contained diagnoses suggesting gestational diabetes

Primary outcomes:
measure: Completion of dilated eye examination
timeFrame: 12-months following intervention
Secondary outcomes:
measure: Completion of glycated hemoglobin testing (HbA1c)
timeFrame: one-year following intervention
measure: Completion of LDL-cholesterol testing
timeFrame: one year following intervention
measure: Completion of microalbumin testing
timeFrame: one-year following intervention
Other outcomes:
Locations:
city: Boston
country: United States
facility: Harvard Pilgrim Health Care
state: Massachusetts
Study officials:
affiliation: Harvard Pilgrim Health Care
name: Steven R Simon, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Simon SR, Trinacty CM, Soumerai SB, Piette JD, Meigs JB, Shi P, Ensroth A, Ross-Degnan D. Improving diabetes care among patients overdue for recommended testing: a randomized controlled trial of automated telephone outreach. Diabetes Care. 2010 Jul;33(7):1452-3. doi: 10.2337/dc09-2332. Epub 2010 Mar 31.